Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
Additional 4-HNE (4-hydroxynonenal) biomarker data to highlight the correlation of bulbar and limb onset ALS (Amyotrophic Lateral Sclerosis) to 4-HNE levels HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024. The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.Dr. Appel previously presented 4-HNE biomarker data in March 2024 at the Society of Neuroimmune Pharmacology Conference showing high correlation (91.7% sensitivity and 71.1% specificity) between the rate of ALS disease progression and survival of patien
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases [Seeking Alpha]Seeking Alpha
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumBusiness Wire
- Coya Therapeutics to Participate in the Mizuho Neuroscience SummitBusiness Wire
COYA
Sec Filings
- 3/29/24 - Form DEFA14A
- 3/28/24 - Form ARS
- 3/28/24 - Form DEFA14A
- COYA's page on the SEC website